Illumina (NASDAQ:ILMN) Sets New 52-Week High – Here’s What Happened

Illumina, Inc. (NASDAQ:ILMN)’s share price hit a new 52-week high on Wednesday . The stock traded as high as $151.76 and last traded at $150.0650, with a volume of 818562 shares trading hands. The stock had previously closed at $147.17.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ILMN shares. Barclays increased their target price on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Evercore ISI restated an “outperform” rating and issued a $155.00 price target on shares of Illumina in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Cowen restated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $124.47.

Illumina Stock Performance

The stock’s 50 day moving average price is $133.32 and its 200 day moving average price is $112.20. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $23.30 billion, a price-to-earnings ratio of 34.19, a P/E/G ratio of 2.35 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the company posted $1.14 earnings per share. The company’s revenue for the quarter was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Transactions at Illumina

In other news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Scott Gottlieb bought 500 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the transaction, the director owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Next Capital Management LLC purchased a new stake in Illumina during the second quarter worth $341,000. CWM LLC lifted its stake in shares of Illumina by 112.9% during the 2nd quarter. CWM LLC now owns 76,711 shares of the life sciences company’s stock worth $7,319,000 after purchasing an additional 40,676 shares during the last quarter. Generali Asset Management SPA SGR lifted its stake in shares of Illumina by 51.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after purchasing an additional 7,574 shares during the last quarter. Andra AP fonden boosted its position in Illumina by 426.3% during the second quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after purchasing an additional 83,017 shares in the last quarter. Finally, Bourgeon Capital Management LLC grew its stake in Illumina by 76.4% in the second quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock valued at $13,538,000 after purchasing an additional 61,468 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.